Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 18/20 | 0.75 |
| ▸ | BRAF | P15056 | 17/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.73 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350529 | 0.89 | RAF1 (0.61) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL2345505 | 0.88 | MAPK14 (0.64) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL2352480 | 0.88 | PKM (0.70) | RAF1BRAF | |
| SCHEMBL2350617 | 0.87 | MAPK14 (0.65) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL2350363 | 0.87 | BRAF (0.72) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL2345373 | 0.86 | MAPK14 (0.64) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL16037261 | 0.86 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL2348485 | 0.85 | MAPK14 (0.62) | RAF1BRAFFGFR1DDR2 | |
| SCHEMBL2342770 | 0.85 | RAF1 (0.69) | RAF1BRAF | |
| SCHEMBL16037223 | 0.84 | RAF1 (1.00) | RAF1BRAFFGFR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008303-B2 | e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | RAF1 2633/4885BRAF 3744/4885FGFR1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.